Pharmacosmos sees big potential in million-dollar acquisition

Family-owned Pharmacosmos wants to grow, which is why the company has paid up to USD 225m for US-based Abfero Pharmaceuticals last week, also acquiring its lead candidate SP-420 that Pharmacosmos says has a promising future ahead.
Photo: Pharmacosmos / PR
Photo: Pharmacosmos / PR
by ANDREAS LØNSTRUP, translated by daniel pedersen

Pharmacosmos took out the the big checkbook last week, when the family-owned company, which is based in Denmark, acquired the privately owned Boston-based business Abfero Pharmaceuticals.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading